Gabrielle Y. Liu

Gabrielle Y. Liu

Auto-generated profile, based on publicly available information

Gabrielle Y. Liu

University of California Davis , Department of Internal Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Sacramento, CA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
GLGabrielle Y. Liu
Gabrielle Y. Liu
SKSadiya S. Khan
Sadiya S. Khan
LCLaura A. Colangelo
Laura A. Colangelo
DMDaniel Meza
Daniel Meza
GWGeorge R. Washko
George R. Washko
RKRavi Kalhan
Ravi Kalhan
In this secondary data analysis of 2674 participants from the CARDIA (Coronary Artery Risk Development in Young Adults) study, 6.5% of patients with 80% to 99% of predicted race-specific FEV1 had r... Visual Racial Differences in Emphysema Prevalence in Adults With Normal Spirometry. In this secondary data analysis of 2674 participants from the CARDIA (Coronary Artery Risk Development i... Background: Computed tomography (CT) imaging complements spirometry and may provide insight into racial disparities in respiratory health. Objective: To determine the difference in emphysema preval...

1 September 2021 in Chest
Verified
Journal Article
Closed access
GLGabrielle Y. Liu
Gabrielle Y. Liu
RKRavi Kalhan
Ravi Kalhan

1 May 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
BCBina Choi
Bina Choi
GLGabrielle Y Liu
Gabrielle Y Liu
QSQuanhu Sheng
Quanhu Sheng
KAKaushik Amancherla
Kaushik Amancherla
APAndrew Perry
Andrew Perry
GWGeorge R Washko
George R Washko
Rationale: Quantitative interstitial abnormalities (QIAs) are early measures of lung injury automatically detected on chest computed tomography scans. QIAs are associated with impaired respiratory health and share features with advanced lung diseases, but their biological underpinnings are not well understood. Objectives: To identify novel protein biomarkers of QIAs using high-throughput plasma proteomic panels within two multicenter cohorts. Methods: We measured the plasma proteomics of 4,383 participants in an older, ever-smoker cohort (COPDGene [Genetic Epidemiology of Chronic Obstructive Pulmonary Disease]) and 2,925 participants in a younger population cohort (CARDIA [Coronary Artery Disease Risk in Young Adults]) using the SomaLogic SomaScan assays. We measured QIAs using a local density histogram method. We assessed the associations between proteomic biomarker concentrations and QIAs using multivariable linear regression models adjusted for age, sex, body mass index, smoking status, and study center (Benjamini-Hochberg false discovery rate–corrected P ≤ 0.05). Measurements and Main Results: In total, 852 proteins were significantly associated with QIAs in COPDGene and 185 in CARDIA. Of the 144 proteins that overlapped between COPDGene and CARDIA, all but one shared directionalities and magnitudes. These proteins were enriched for 49 Gene Ontology pathways, including biological processes in inflammatory response, cell adhesion, immune response, ERK1/2 regulation, and signaling; cellular components in extracellular regions; and molecular functions including calcium ion and heparin binding. Conclusions: We identified the proteomic biomarkers of QIAs in an older, smoking population with a higher prevalence of pulmonary disease and in a younger, healthier community cohort. These proteomics features may be markers of early precursors of advanced lung diseases.

27 August 2024 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Open access
KAKatyayini Aribindi
Katyayini Aribindi
GLGabrielle Y. Liu
Gabrielle Y. Liu
TATimothy E Albertson
Timothy E Albertson
Idiopathic pulmonary fibrosis (IPF) is a progressive-fibrosing lung disease with a median survival of less than 5 years. Currently, two agents, pirfenidone and nintedanib are approved for this disease, and both have been shown to reduce the rate of decline in lung function in patients with IPF. However, both have significant adverse effects and neither completely arrest the decline in lung function. Thirty experimental agents with unique mechanisms of action that are being evaluated for the treatment of IPF are discussed. These agents work through various mechanisms of action, these include inhibition of transcription nuclear factor k-B on fibroblasts, reduced expression of metalloproteinase 7, the generation of more lysophosphatidic acids, blocking the effects of transforming growth factor ß, and reducing reactive oxygen species as examples of some unique mechanisms of action of these agents. New drug development has the potential to expand the treatment options available in the treatment of IPF patients. It is expected that the adverse drug effect profiles will be more favorable than current agents. It is further anticipated that these new agents or combinations of agents will arrest the fibrosis, not just slow the fibrotic process.

1 January 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
GLGabrielle Y. Liu
Gabrielle Y. Liu
APAndrew S. Perry
Andrew S. Perry
GWGeorge R. Washko
George R. Washko
EFEric Farber-Eger
Eric Farber-Eger
LCLaura A. Colangelo
Laura A. Colangelo
RKRavi Kalhan
Ravi Kalhan
Rationale: Accelerated decline in lung function is associated with incident chronic obstructive pulmonary disease (COPD), hospitalization, and death. However, identifying this trajectory with longitudinal spirometry measurements is challenging in clinical practice. Objectives: To determine whether a proteomic risk score trained on accelerated decline in lung function can assess the risk of future respiratory disease and mortality. Methods: In the Coronary Artery Risk Development in Young Adults Study, a population-based cohort starting in young adulthood, longitudinal measurements of FEV1 percent predicted (up to six time points over 30 yr) were used to identify accelerated and normal decline trajectories. Protein aptamers associated with an accelerated decline trajectory were identified with multivariable logistic regression followed by LASSO (least absolute shrinkage and selection operator) regression. The proteomic respiratory susceptibility score was derived on the basis of these circulating proteins and applied to the U.K. Biobank (UKBB) and COPDGene studies to examine associations with future respiratory morbidity and mortality. Measurements and Main Results: Higher susceptibility score was independently associated with all-cause mortality (UKBB hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.50–1.61; COPDGene HR, 1.75 95% CI, 1.63–1.88), respiratory mortality (UKBB HR, 2.39; 95% CI, 2.16–2.64; COPDGene HR, 1.81; 95% CI, 1.32–2.47), incident COPD (UKBB HR, 1.84; 95% CI, 1.71–1.98), incident respiratory exacerbation (COPDGene odds ratio, 1.10; 95% CI, 1.02–1.19), and incident exacerbation requiring hospitalization (COPDGene OR, 1.17; 95% CI, 1.08–1.27). Conclusions: A proteomic signature of increased respiratory susceptibility identifies people at risk of respiratory death, incident COPD, and respiratory exacerbations. This susceptibility score is composed of proteins with well-known and novel associations with lung health and holds promise for the early detection of lung disease without requiring years of spirometry measurements.

26 June 2026 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
SGSheiphali A Gandhi
Sheiphali A Gandhi
GLGabrielle Y Liu
Gabrielle Y Liu
JFJane C Fazio
Jane C Fazio
OAOlawale Amubieya
Olawale Amubieya
HBHayley Barnes
Hayley Barnes
BNBenoit Nemery
Benoit Nemery
Artificial stone–associated silicosis (AS silicosis) has emerged over the past decade as a severe, rapidly progressive, and preventable occupational lung disease affecting workers who manufacture, fabricate, and install artificial stone countertops. Characterized by short latency, accelerated progression, and high morbidity and mortality, AS silicosis disproportionately affects young workers employed in precarious conditions. In response to the growing global burden of disease, this American Thoracic Society workshop was convened in 2025 to review the current state of knowledge regarding AS silicosis, synthesize the current evidence, and identify priorities for research, clinical care, public health surveillance, and prevention. Workshop participants reviewed data spanning exposure science, epidemiology, clinical manifestations, health equity, and policy responses. Evidence demonstrates that artificial stone (AS) dust is highly toxic, containing high concentrations of respirable crystalline silica, resin-derived volatile compounds, and trace metals, resulting in exposures that routinely exceed occupational exposure limits. Despite widespread implementation of wet methods, ventilation, and respiratory protection, hazardous exposures persist across diverse settings globally, highlighting fundamental limitations of existing control strategies. Clinically, AS silicosis is associated with high rates of progressive massive fibrosis, autoimmune disease, infection, respiratory failure, and increasing need for lung transplantation. Treatment options remain limited, underscoring the importance of early detection and exposure cessation. The workshop identified critical gaps in medical screening and public health surveillance worldwide, with inconsistent regulatory frameworks, low compliance, underreporting, and delayed diagnoses. Case detection is often dependent on symptomatic presentation rather than proactive screening, exacerbating disease severity and inequities in care. International experiences illustrate both the consequences of regulatory inaction and the potential impact of decisive interventions, including Australia’s prohibition of crystalline silica–containing artificial stone. This report concludes that AS silicosis represents a failure of primary prevention and calls for coordinated global action. Key priorities include strengthening surveillance systems, ensuring equitable access to screening and care, developing effective therapeutics, advancing exposure science, and implementing higher-order preventive strategies, including the elimination or substitution of high-silica AS. Without urgent and sustained intervention, these products will continue to impose devastating and avoidable harm on workers worldwide.